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ABSTRACT
The bias of A-rich codons in HIV-1 pol is thought to
be a record of hypermutations in viral genomes that
lack biological functions. Bioinformatic analysis
predicted that A-rich sequences are generally
associated with minimal local RNA structures.
Using codon modifications to reduce the amount
of A-rich sequences within HIV-1 genomes, we
have reduced the flexibility of RNA sequences in
pol to analyze the functional significance of these
A-rich ‘structurally poor’ RNA elements in HIV-1
pol. Our data showed that codon modification of
HIV-1 sequences led to a suppression of virus infec-
tivity by 5–100-fold, and this defect does not corre-
late with, viral entry, viral protein expression levels,
viral protein profiles or virion packaging of genomic
RNA. Codon modification of HIV-1 pol correlated
with an enhanced dimer stability of the viral RNA
genome, which was associated with a reduction of
viral cDNA synthesis both during HIV-1 infection and
in a cell free reverse transcription assay. Our data
provided direct evidence that the HIV-1A-rich pol
sequence is not merely an evolutionary artifact of
enzyme-induced hypermutations, and that HIV-1
has adapted to rely on A-rich RNA sequences to
support the synthesis of viral cDNA during reverse
transcription, highlighting the utility of using
‘structurally poor’ RNA domains in regulating bio-
logical process.
INTRODUCTION
Proteins are often thought to be the prime regulator of
biological systems, but it is now appreciated that RNA
has a much greater role in the regulation of biological
processes than previously thought (1,2). It has been esti-
mated that less than 2% of the human genome codes for
proteins, but more than 90% of the human genome is
transcribed in diﬀerent cells (3). This vast diﬀerence
between mRNA and non-protein coding RNA transcrip-
tion suggests (a) the existence of an uncharacterized func-
tional RNA-based regulation network and/or (b) the
presence of a large quantity of non-functional-junk
RNA transcripts within the cell. The existence of these
vast quantities of non-coding RNAs in cells implies the
signiﬁcance of these diﬀerential RNA species in the regu-
lation of biological processes (1,4). The discovery of RNA
interference (RNAi) and microRNA (miRNA) highlights
a complex and dynamic coordination network that exists
through RNA elements. Recent works have shown that
viruses have evolved to manipulate many of these same
RNA networks to support their own replications (5,6). It
is safe to assume that the microRNA network is not likely
to be the last example demonstrating how organisms have
developed ingenious ways to regulate biological process
via RNA sequences.
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tide contents of the RNA sequences. With the exception
of methionine and tryptophan, all amino acids can be
coded by more than one codon. However, synonymous
codons are rarely used with equal frequency and patterns
of codon usage can vary between individual genes and
even complete genomes, and the genomes of RNA viruses
are no exception. In a recent analysis of 50 human RNA
viruses, a diverse array of codon usage patterns was
observed (7). Intriguingly, the nucleotide composition pre-
ferred by a given RNA virus does not always conform to
the composition observed in the host organism in which
it replicates. The striking preference for A-rich codons in
the human immunodeﬁciency virus-type 1 (HIV-1) is well
established (8–10) and clearly contrasts with the G-rich
codon usage seen in mammalian cellular protein synthesis.
The typical nucleotide composition of HIV-1 is  36% A,
23% G, 19% C and 22% T, with some strains (such
as strain O) comprised greater than 40% A (11). The
A-rich codon usage bias is apparent in each of HIV-1’s
three major coding regions; gag, pol and env, but is most
pronounced in the pol gene (12–14). Bioinformatic analy-
sis would predict that the bias of A-rich nucleotides in
the HIV-1 genome will limit the formation of stable
local RNA structures in selected regions of viral genomes,
and it is unclear whether these A-rich ‘structurally
poor’ RNA elements are important for the propagation
of HIV-1.
There are several non-mutually exclusive hypotheses as
to why these A-rich sequences have evolved in the HIV-1
genome. For example, early work suggested that an imbal-
ance in the pyrimidine nucleoside pool of infected cells
during reverse transcription could enhance the G-to-A
mutation frequency (15,16). It has also been proposed
that the low ﬁdelity of reverse transcriptase (RT) may be
responsible for HIV-1’s codon usage bias. This position
emerged from the observation that the most common
error made during reverse transcription of HIV-1 in
single replication experiments is a G-to-A mutation (17).
More recently, it has been thought that the host cytidine
deaminase APOBEC3G may have driven the evolution of
the A-rich HIV-1 genome (18–22). Nucleic acid editing by
APOBEC3G is thought to be an ancient form of host-cell
innate immunity (23). It is thought that virion incorpora-
tion of APOBEC3G triggers the deamination of cytosine
to uracil on the negative sense single-stranded DNA
that is produced during reverse transcription and results
in the incorporation of A instead of G in the proviral plus-
sense DNA strand (24). Viral strategies have evolved to
limit G-to-A hypermutation. The role of the HIV-1 acces-
sory protein Vif includes blocking the packaging of
APOBEC3G, and thereby removes the opportunity for
APOBEC3G to attack the viral genome (25). While Vif
is now recognized to be central to HIV-1’s evasion of the
host-defence response, the evolutionary pathway traversed
in the development of this strategy may be visible in HIV-
1’s A-rich genome.
In a virus renowned for making the most of it is com-
pact genome, it is unlikely that HIV-1’s A-rich genome
is merely a ‘record’ left behind by one or all of these
hypermutation mechanisms. To assess the role of A-rich
structurally poor RNA elements in HIV-1 replication, we
have systematically replaced wild-type (WT) A-rich
regions of gag and pol with codon-modiﬁed G-rich RNA
segments without altering the amino-acid sequences.
The A-to-G substitution will have little impact on existing
A-U base-pairing as G-U also base pairs. The substitution
of A-to-G will also enable original unpaired nucleotides
to basepair with either U or C nucleotide. In contrast to
the codon optimized expression vectors, partial replace-
ment of the A-rich HIV-1 sequences with G-rich sequences
in the context of the full-length HIV-1 genome did not
alter the level of overall viral protein production. Codon
modiﬁcation of HIV-1 pol led to more pronounced
defects in viral replication. These defects in viral replica-
tion correlated with an enhancement of genomic RNA
dimer stability and a reduction of viral cDNA synthesis.
Our results support the notion that the A-rich structurally
poor elements of HIV-1 pol are important for viral repli-
cation by maintaining the structural ﬂexibility of the
dimeric RNA that is critical for the synthesis of viral
cDNA genomes during infection. This work provides
experimental evidence illustrating that the ﬂexibility of
RNA molecules is an important regulator of biological
processes.
MATERIALS AND METHODS
Construction of full-length HIV-1 DNA plasmids
The HIV-1 DNA constructs were derived from the full-
length WT HIV-1 plasmid NL4.3 (26). Three codon-
modiﬁed HIV-1 mutants were created with altered
genomic RNA base sequences in gag and/or pol that
retain the WT amino-acid sequences of the expressed
viral proteins. WT A-rich regions in the NL4.3 plasmid
were replaced with the equivalent regions from a G-rich
Gag/Gag-Pol vector (phGag-Pol) (27). The phGag-Pol
vector is codon modiﬁed (G-rich) throughout, with the
exception of the sequences where gag and pol overlap
(between amino acids NC53 in Gag and PR23 in Pol).
These sequences remain A-rich to allow normal produc-
tion of the Gag-Pol polyprotein via frameshifting (27).
The mutants are depicted in Figure 1 and have been
Figure 1. Schematic representation of the NL4.3-based constructs used
in this study. The codon-modiﬁed regions are indicated.
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replaced sequence: (i) NL h
 CA173-NC53/PR17–23, (ii) NL
h
 CA173-NC53/PR17-RT463 and (iii) NL h
 PR23-RT463.
PCR site directed mutagenesis was performed in the WT
NL4.3 plasmid as previously described (28). The codons at
amino acid 173 in CA (CA173), amino acid 23 in PR
(PR23) and/or amino acid 463 in RT (RT463) were mod-
iﬁed to introduce the restriction sites BssHII, XbaI and/or
NotI, respectively, without altering the amino-acid
sequence. The introduced restriction sites were then used
to replace the WT A-rich NL4.3 sequences with the
corresponding G-rich sequence from phGag-Pol.
Replacement of the 620bp BssHII-XbaI region (between
amino acids CA173 and PR23) generated NL h
 CA173-
NC53/PR17–23. Similarly, replacement of the entire
2230bp BssHII-NotI region (between amino acids CA173
and RT463) yielded NL h
 CA173-NC53/PR23-RT463 and
replacement of the 1610-bp XbaI-NotI region (between
amino acids PR23 and RT463) generated NL h
 PR23-
RT463. All mutant sequences were conﬁrmed by sequenc-
ing analysis.
Virus production
293T cells were used for transient transfection. The cells
were maintained in Dulbecco’s Modiﬁed Eagle’s Medium
(Gibco BRL) containing 10% heat-inactivated foetal
bovine serum (P. A. Biological Co.) and 1% penicillin–
streptomycin. Virus stocks were produced using either
the calcium phosphate co-precipitation method or poly-
ethylenimine (PEI) for the transient transfection. For cal-
cium phosphate transfection, 10mg of DNA from each of
the HIV-1 constructs was routinely used. The enhanced
green ﬂuorescent protein (EGFP, Clonetech) reporter
plasmid (2mg) was included to monitor transfection eﬃ-
ciency. For PEI transfection, 3mg of DNA from each
HIV-1 construct was used. Supernatants and cells were
collected at 36h post-transfection and separated by centri-
fugation for 30min at 3000rpm (Beckman Model GS-6).
The RT activity of cell culture supernatants was measured
utilizing a micro-RT assay as previously described (29).
Viral infectivity in peripheral bloodmononuclear cells
(PBMCs)
PBMCs were isolated from HIV-seronegative buﬀy coats
(supplied by the Red Cross Blood Bank, Melbourne,
Victoria, Australia) as previously described (30). PBMCs
were stimulated with 10mg/ml of phytohemagglutinin
(Murex Diagnostics) and maintained in RPMI (Roswell
Park Memorial Institute) 1640 medium (Gibco) contain-
ing 10% fetal bovine serum, gentamicin, glutamine and
5% interleukin-2 (Boehringer) for 3 days. Viral super-
natants, which were normalized for RT activity, were
then mixed with 10
5 PBMCs in a 96-well tissue culture
plate. Eight 10-fold dilutions of each virus were tested in
triplicate. A half media change was carried out every 3–4
days. Viral infectivity was assessed by monitoring RT
activity, as described above, with supernatants collected
on day 3, 7, 10 and 14 post-infection. Infectivity was quan-
tiﬁed using TCID50.
Proteinisolation, quantification of virion proteins and
western blot analysis
Intracellular viral protein was isolated from transfected
293T cells by washing cells twice with 1  phosphate buﬀ-
ered saline (PBS) then lysing with 2  Tris-buﬀered saline
(TBS) lysis buﬀer containing 1% Nonidet P-40, 20mM
phenylmethyl sulfonyl ﬂuoride (PMSF), 1mM pepstatin
and 1mM leupeptin. Cell lysates were freeze-thawed in
liquid nitrogen and then clariﬁed by centrifugation for
20min at 14000rpm. Virion protein was obtained by
ultracentrifugation (Beckman model L-90, SW 41 rotor)
of the transfection supernatants at 35000rpm for 1h at
48C through a 20% sucrose cushion. The viral pellets were
resuspended in 50ml2   TBS lysis buﬀer. Western blot
analysis was carried out as previously described (31),
using pooled sera from HIV-1 infected patients to detect
total HIV-1 proteins.
Analysisof virion RNA packaging
Pelleted virions were prepared by ultracentrifugation as
described above and resuspended in 500ml Trizol
(GIBCO). Following incubation for 30min on ice to
allow lysis, the samples were phenol/chloroform extracted
and genomic RNA was isolated as previously described
(32,33). A standard curve of WT RNA was prepared con-
sisting of 150%, 100%, 50% and 10% of WT HIV-1.
Samples were normalized by total virion proteins.
Samples were heat denatured at 688C for 15min and
then separated by electrophoresis in a 1% denaturing
agarose gel. Samples were transferred onto a Hybond N
membrane (Amersham Pharmacia Biotech). RNAs were
hybridized with a radioactive riboprobe (pGEM7zHIV-1),
which is complimentary to the 5 end of the HIV-1 genomic
RNA (28,30–33).
Analysisof virion RNA dimerstability
Viral supernatants were puriﬁed and concentrated by
ultracentrifugation as described above. Virion pellets
were resuspended in 500ml of RNA dimer lysis buﬀer
[10mM Tris (pH 7.5), 1mM EDTA, 1% SDS, 50mM
NaCl, yeast tRNA at 50mg/ml and proteinase K at
100mg/ml], phenol/chloroform extracted and isolated for
melting curve analysis as previously described (34,35).
Similar amounts of genomic RNA were used to analyze
the stability of the virion RNA dimer as previously
described (28,30,36). Brieﬂy, RNA samples that had
been heat denatured for 10min at either 408C, 438C,
468C, 498C, 528Co r5 5 8C were separated by electrophor-
esis in a 1% native agarose gel in 0.5  Tris–borate–EDTA
buﬀer. Samples were transferred onto a Hybond N mem-
brane (Amersham Pharmacia Biotech). Dimeric and
monomeric RNAs were hybridized with a radioactive
riboprobe (pGEM7zHIV-1) as above.
Assessment ofreverse transcription competency in
infected cells
Viral stocks derived from transfected 293T cells were ﬁl-
tered (0.22mm), concentrated by ultracentrifugation then
normalized by p24 Gag ELISA (Vitroniska). The viral
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for 30min at 378C in the presence of 0.01M MgCl2.
An aliquot of each DNase-treated viral stock was heat-
inactivated (568C for 1h) prior to infection to monitor
plasmid DNA contamination from the transfection. WT
and mutant virions were used to infect PHA-stimulated
PBMCs pooled from two donors at 500ng p24 per 10
5
cells. At 24h post-infection, the PBMCs were washed in
PBS and then lysed in PCR lysis buﬀer [10mM Tris pH8,
1mM ethylenediamine tetra-acetic acid, 0.002% (vol/vol),
Triton X-100, 0.002% (wt/vol) sodium dodecyl sulfate and
proteinase K at 0.8mg/ml]. The lysates were incubated at
568C for 1h, followed by heat inactivation of proteinase K
for 10min at 958C.
The PBMC lysates were assessed via real-time PCR
using the iCycler iQ (BIO-RAD). The HIV-1 based prim-
ers utilized to detect early and late reverse transcription
products have been previously described (37,38). The
primer pair AA55/M667 that ampliﬁes the R-U5 region
of the LTR was used to detect the early reverse transcrip-
tion products of minus-strand strong stop DNA (ssDNA).
The primer pair M661/M667 that ampliﬁes within the
LTR/gag region was used to detect complete HIV-1
cDNA. The PCR reactions were performed using
SYBER green I (BIO-RAD) with the PCR conditions pre-
viously described by Victoria et al. (38). Input cell num-
bers were normalized by quantifying CCR5 (39).
Invitro reverse transcription assay
A 220-nucleotide-long HIV sequence corresponds to the
coding sequence of last 13 amino acids of p2 and ﬁrst 60
amino acids of NC were cloned out from NL4.3 and NL
h
 CA173-NC53/PR17–23, respectively. These sequences
were engineered into in vitro transcription vector. RNA
templates were prepared from plasmids digested by
SmaI and in vitro transcribed, with T7 RNA polymerase
as previously described (40). WT and NL h
 p2-NC53
RNAs were puriﬁed by gel ﬁltration. DNA primer
(NL4255a: 50 TTCCCTAAAAAATTAGCCTGTC 30
that corresponds to the coding sequences of NC54–60)
were chemically synthesized and 50-end-labeled with
[g-
32P]ATP (Perkin Elmer) and polynucleotide kinase
from phage T4 (Fermentas). RT
E478Q, lacking RNase H
activity, was a gift from G. Bec and was puriﬁed according
to a protocol kindly provided to us by Dr Torsten Unge
(Uppsala, Sweden).
For reverse transcription experiments, template RNAs
WT and codon-modiﬁed HIV sequences were hybridized
with
32P-labelled primer NL4255a and template RNAs
at a 3:1 molar ratio. Hybridization eﬃciency was checked
on a native 12% polyacrylamide gel. Primer/template
duplexes (10nM ﬁnal concentration) were pre-incubated
with RT (10nM ﬁnal concentration) at 378C for 4min,
in 50mM Tris–HCl pH 8.3 (378C), 50mM KCl, 6mM
MgCl2 and 1mM DTT. Reverse transcription was
initiated by the addition of 50mM of each of the four
deoxyribonucleoside triphosphates. Reactions were
stopped at 30s, 1, 5, 15, 30 and 60min by the addition
of formamide and reaction products were analyzed on
denaturing 8% polyacrylamide-urea gels and quantiﬁed
with a Bioimager.
b-Lactamase entry assay
MT2 cells (5  10
5) were incubated with virions produced
through PEI transfection of 3mg of appropriate proviral
DNA and 1.5mg pMM310 (a b-lactamase-Vpr plasmid,
kindly donated by M. Miller, Merck Research
Laboratories) (50ng p24-Gag) at 378C for 1h. Cells that
were not exposed to virus were used as a negative control
for virus entry. Cells were washed in CO2-independent
media (CO210, Gibco BRL) containing 10% Cosmic
Calf Serum without antibiotics. Cells were then resus-
pended in 100mlC O 210 containing 2.5mM probenecid
and 20ml of CCF2/AM dye prepared as per manufac-
turer’s instructions (Invitrogen), then incubated at room
temperature for 7h protected from light. Cells were
washed once with PBS and then ﬁxed in a 4% solution
of paraformaldehyde. The change in emission ﬂuorescence
of CCF2 after cleavage by the b-lactamase-Vpr plasmid
was monitored by ﬂow cytometry with a three-laser FACS
ARIA (Becton Dickinson). CCF2 ﬂuorescence was excited
using a Violet 407nm laser emission. Blue emission was
detected at 450nm BP (450/40=range 410–490nm); green
emission was detected with a 502nm LP and a 520nm BP
(520/30=range 490–550nm).
RESULTS
Codon modification and inscilico analysis ofthe folding
potential of HIV-1 RNA sequences
The unusually high levels of A-rich sequences in pol sug-
gest that the local RNA sequences within pol would have a
ﬂexible structure and a low folding potential to form
stable RNA elements. By taking advantage of the existing
codon-modiﬁed HIV-1 genomes in the literature (27), we
have codon modiﬁed the HIV-1 pol in the context of the
full length HIV-1 genome (without changing the amino
acids) to examine the role of A-rich RNA sequences in
viral replication. Using the full-length NL4.3 strain of
HIV-1 as the parental backbone, the RNA sequences cor-
responding to coding sequences from amino acid 23 of
protease (PR23) to amino acid 463 of reverse transcriptase
(RT463) were codon modiﬁed for analysis (Figure 1). RNA
sequences corresponding to coding sequences from amino
acid 173 of capsid (CA173) to amino acid 53 of nucleocap-
sid (NC53)i ngag were also codon modiﬁed for compar-
ison. A mutant containing codon modiﬁcation in both gag
(CA173-NC53) and pol (PR23-RT463) was also included in
the study.
RNA sequences upstream of the coding sequence of
CA173 were left untouched due to the existence of a
number of well deﬁned cis-acting instability elements in
gag (41). Similarly, the coding sequence of the major
homology region of capsid protein has not been modiﬁed
as this region has been implicated to be important for the
traﬃcking of HIV-1 RNA (42–44). The coding sequences
from NC53 to PR23 were unmodiﬁed as they consist of
RNA frameshift elements and overlapping reading
frames of Gag and Pol (45). The coding sequence of
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sequences (46,47). It is conceivable that some of the yet to
be identiﬁed RNA structures within these codon-modiﬁed
segments might be abolished through these codon modiﬁ-
cations (48).
As biochemical analysis of RNA structures of HIV-1
pol is currently lacking, a bioinformatic approach was
employed to estimate the RNA folding potentials of our
codon-modiﬁed HIV-1 genomes. Energy diﬀerence scan
(EDscan) (49), a program for analysis of well-ordered
folding segments in nucleotide sequences, was used. By
ﬁxing a window size of 70, 80, 90 or 100-nucleotides,
the lowest free energy of the optimal structure folded by
the segment was calculated. Regardless of the window size
used for analysis, the codon-modiﬁed genomes consis-
tently had lower free energy values than the unmodiﬁed
control and a higher probability to form stable RNA
structures. Furthermore, in accordance with the enrich-
ment of A-rich nucleotides in pol, the local minimum
free energy values for unmodiﬁed pol sequences were gen-
erally higher than the free energy values for unmodiﬁed
gag, implicating that the RNA structures in HIV-1 pol is
more ﬂexible than in gag. These points were veriﬁed with
whole genome folds (Figure 2) that considered a range of
optimal and sub-optimal conﬁgurations for each intact
RNA. When measured for the optimal folds, the largest
genome-wide change in A content (36% vs. 32%),
between WT (NL4.3) and mutant (NL h
 CA173-NC53/
PR17-RT463), showed the largest corresponding shift
in total basepair composition, with AU:GC ratios con-
verting from 46:43% to 40:50%, respectively, and the
genome minimum energy (dG) shifting equivalently
lower ( 2096kcal vs. –2388kcal). Despite these signiﬁcant
composition changes, the optimal and suboptimal data
also predicted the global topological changes for each
RNA are primarily restricted to within a few hundred
nucleotides of the altered bases. That is, outside of the
gag–pol genes themselves, and a few local perturbations
in the 30-most 150 bases, the remainder of the unmodiﬁed
and codon-modiﬁed genomes took similar conﬁgurations
over a wide range (optimal plus >20kcal) of sampled
energies.
A-rich RNA sequences of theHIV-1 pol arecritical for
viral replication
The biological impact of the ﬂexibility of HIV-1 pol RNA
sequences on HIV-1 biology was assessed using WT and
codon-modiﬁed HIV-1. WT and mutant virions derived
from transfection of proviral DNA into 293T cells were
normalized for RT activity and assayed for infectivity in
three diﬀerent PBMCs donors. To directly assess the rel-
ative infectivity of mutant and WT HIV-1, tissue culture
infectious dosage 50% (TCID50) calculations were per-
formed on day 10 of infection (Figure 3A). The two
mutants with G-rich pol regions, NL h
 CA173-NC53/
PR23-RT463 and NL h
 PR23-RT463 were 30–100-fold less
infectious than WT, while the mutant NL h
 CA173-NC53/
PR17–23, which is codon modiﬁed in gag but remains
A-rich in PR-RT was  5-fold less infectious than WT
(Figure 3A). The replication kinetics of these viruses
also diﬀered (Figure 3B). NL h
 CA173-NC53/PR23-RT463
was non-infectious. NL h
 PR23-RT463 demonstrated
dramatically reduced infectivity when compared to WT,
but displayed a slight increase in virus production over
the time course (Figure 3B). The replication kinetics
of NL h
 CA173-NC53/PR17–23 were delayed when com-
pared to WT; however, viral production was similar to
that of WT by day 14. Overall, these results point to
an important role for HIV-1’s A-rich sequences in viral
infectivity and suggest that the A-rich RNA sequences
in the PR-RT region of the pol gene are critical for
replication.
Partial codon modification of HIV-1 can alter virionprotein
processing butdoes notenhance viral protein expression
Previous studies have shown that expressions of the
codon-modiﬁed HIV-1 gene in expression constructs
signiﬁcantly enhance the levels of viral protein expression
by a factor of 10 through bypassing the Rev-dependent
mechanism (27,50,51). One would expect that if our codon
modiﬁcations had altered critical unknown cis-acting
instability elements (INS) in gag and pol, an enhanced
level of viral protein expression would be detected.
Western blot analysis was performed on viral proteins
produced in transfected 293T cells using HIV-1 pooled
patient sera. Loading volumes were normalized for
transfection eﬃciency based on the expression of the
co-transfected EGFP. Overall the intracellular protein
proﬁles of the codon-modiﬁed mutants were compara-
ble but not identical to WT (Figure 4A). In the intracel-
lular protein proﬁle of NL h
 PR23-RT463, we observed
an additional 90kDa protein (Figure 4A). Based on size,
this protein is most likely to be an uncleaved RT-IN inter-
mediate. Puriﬁed viral particles were also analyzed by
western blotting. Diﬀerences were seen with the protein
proﬁles of the three codon-modiﬁed mutants in compari-
son with the WT (Figure 4B). It is important to note that
viral protein expression levels in the three codon-modiﬁed
constructs were comparable to WT. These results contrast
with previous studies (27,50,51), highlighting that our
codon-modiﬁed HIV-1 RNA genomes (perhaps due to
the presences of Rev responsive elements) are not likely
to alter the viral RNA traﬃcking network or inﬂuence the
levels of viral protein expression.
Flexibility of HIV-1 RNA sequences inpol isanegative
regulator ofgenomic RNA dimer stability
The virion packaging of RNA genomes and the stability
of RNA dimers in the codon-modiﬁed HIV-1 were also
examined. For analysis of genomic RNA packaging,
samples were normalized on the basis of total viral pro-
tein. A standard curve of WT genomic RNA packaging
was constructed from four dilutions (150%, 100%, 50%
and 10%). The levels of virion genomic RNA packaging
in these codon-modiﬁed HIV mutants varies from 50% to
80% of RNA genomes found in WT HIV (Figure 5A).
Analysis of genomic RNA dimer stability showed that
dimeric RNA was present in all viruses (Figure 5B).
WT genomic virion RNA was fully dissociated from
dimeric to monomeric RNA at 468C. When compared to
Nucleic AcidsResearch, 2009, Vol.37,No. 3 949WT, the stability of the dimeric RNA was increased
in mutants with codon modiﬁcation in pol sequences
(NL h
 CA173-NC53/PR23-RT463 and NL h
 PR23-RT463)
(Figure 5B), whereas the dimer stability of NL h
 CA173-
NC53 was only mildly aﬀected in comparison with the WT
control (Figure 5B).
A-rich sequences in HIV-1 areessential for reverse
transcription
One of the key roles of dimeric RNA genomes in retro-
viruses is to enable inter-mixing of genomic sequences
during reverse transcription, which ultimately maintains
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Figure 2. Computer-prediction showing the topology of the single stranded RNA of the WT and codon-modiﬁed constructs. The folds were prepared
by using the mfold program and presented (A–D) as the global MinE structure with bases colored according to their P-num values (72). Low P-num
values (<3%) are represented by red bases, while increasing P-num values are represented by the colors orange, yellow, green (medium) and blue
through black (high). The sequence and global MinE structure for NL4.3 were compared to each of the three mutant datasets (E–G). For each paired
series, a sliding window 30 residues wide, tabulated the percent of bases with changed sequence (red), and the percent of bases which took diﬀerent
pairing partners (blue). The data are plotted for every comparative window across the genome length. Genome landmarks include gag (b 336–1835),
pol (b 1631–4639), env (b 5767–8329) and the RRE (b 7294–7541).
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tion could interfere with the reverse transcription process,
the generation of early and late reverse transcription
products was monitored using real-time PCR (38).
The M667-AA55 primer pair was used to amplify the
minus-strand ssDNA, the M667-M661 primer pair was
used to amplify the complete viral cDNA. The primer
positions are depicted in Figure 6A. Potential contamina-
tion from transfected plasmid DNA was measured in sam-
ples infected with heat-inactivated virus, and ampliﬁcation
from these control samples was consistently less than 1%
of the WT ‘live-virus’ infection sample, suggesting that
contaminating plasmid DNA was negligible. Results rep-
resentative of three separate infections are presented in
Figure 6B. The level of minus-strand ssDNA detected
was dramatically reduced in each of the mutants, and
accordingly, the detectable complete viral cDNA is also
reduced. It is worth noting that although NL h
 CA173-
NC53/PR17–23 was observed to have only mildly altered
RNA dimer stability, the capacity of NL h
 CA173-NC53/
PR17–23 to synthesize viral cDNA was signiﬁcantly sup-
pressed (Figure 6). These results suggest a critical role
for A-rich sequences in both HIV-1 gag and pol to support
the synthesis of viral cDNA during reverse transcription.
A reduction of viral cDNA synthesis was also observed
when codon-modiﬁed RNA and corresponding WT
in vitro transcribed RNAs were used as templates for
in vitro reverse transcription assay (Figure 6C). Using
WT A-rich RNA as template, the completion of viral
cDNA synthesized can be detected as early as 5min
after the initiation of the in vitro reverse transcription,
with 20% of the total labeled primers were detected with
the completed viral cDNA at the end of reaction
(Figure 6C). In contrast, when codon-modiﬁed RNA
were used as template for in vitro reverse transcription,
the synthesis of complete viral cDNA can only be detected
30min post the initiation of the reaction, with only 2%
(10-fold less) of the radioactive primers being part of the
viral cDNA 60min after the reverse transcription has
started (Figure 6C).
Viral entry isunaffected in codon-modified HIV-1
To verify that the observed defect in reverse transcription
in the codon-modiﬁed mutants was not due to an
Figure 3. Partial codon modiﬁcation of the HIV-1 genome impairs viral replication in PBMCs. (A) Virion infectivity (TCID50) of WT and mutant
HIV-1 in PBMCs. The values shown are per 10
2 infectious particles/ml. (B) Replication kinetics of the WT and mutant HIV-1 in PBMCs. Freshly
isolated PBMCs were stimulated with PHA for 3 days and then infected with either WT (NL4.3) or mutant virions. Infectivity was monitored as RT
activity in the culture supernatants, which were collected 3, 7, 10 and 14 days after infection. The results represent the mean of duplicate samples.
AB
Figure 4. Partial codon modiﬁcation of the HIV-1 genome can alter
virion protein processing. Intracellular (A) and virion lysates (B) were
produced from transfections in 293T cells, resolved by SDS–PAGE
(10%) and probed with sera from HIV-1 infected individuals.
Nucleic AcidsResearch, 2009, Vol.37,No. 3 951upstream defect in viral entry, a b-lactamase based viral
entry assay was utilized (52). Viruses were produced by
cotransfecting 293T cells with proviral DNA and the
b-lactamase-Vpr (BlaM-Vpr) expression vector. The resul-
tant WT and mutant virions were used to infect target cells
MT2 with CCF2 dye. Upon successful virus entry, CCF2
was cleaved by the virion-associated BlaM enzyme, which
resulted in a change of its ﬂuorescence emission spectrum
from green (520nm) to blue (447nm) (52). Our results
show that similar amounts of blue cells were detected in
our WT and mutant HIV-1 infected samples, indicating
codon-modiﬁed HIV-1 were not defective in virus entry
(Figure 7).
DISCUSSION
This work provides evidence of a role for the A-rich
RNA genome of HIV-1 in viral replication. Each of the
mutants with codon modiﬁcation of gag or pol showed
dramatic impairment in viral replication. NL h
 CA173-
NC53/PR17–23 was less infectious than WT HIV-1 with
5-fold less infectious particles. The two HIV-1 mutants
with codon modiﬁcation in pol were dramatically more
impaired, as NL h
 PR23-RT463 and NL h
 CA173-NC53/
PR23-RT463 were non-infectious in PBMCs and had
30–100 less infectious particles than WT (Figure 3). The
A-rich bias is most pronounced in the pol gene (14), and
codon modiﬁcation to this region produced more dra-
matic changes to viral replication than changes made pri-
marily to the gag gene. The diﬀerence in infectivity
between the G-rich gag mutant (NL h
 CA173-NC53/
PR17–23) and the G-rich pol mutants (NL h
 PR23-RT463
and NL h
 CA173-NC53/PR23-RT463) also indicates that
diﬀerent segments of HIV-1’s A-rich genome may have
distinct functions. One possibility is that the PR-RT
regions of pol contain one or more yet to be identiﬁed
RNA motifs that are important for viral replication (48).
The fact that an A-rich genome is a conserved feature in
all lentiviruses (7,10) points to a critical role for this codon
25 40 43 46 49 52 55
A
B
°
Figure 5. The impact of partial codon modiﬁcation of the HIV-1 genome on virion genomic RNA packaging and dimerization. (A) Viral RNA
packaging was examined using northern analysis. WT and mutant genomic RNA was heat denatured for 15min at 688C. Samples were then
electrophoresed in a 1% native agarose gel and probed with an HIV-1 riboprobe. (B) Virion RNA dimerization was assessed with melting curve
and electrophoretic analysis. WT and mutant virion RNA was resuspended in RNA dimerization buﬀer and heat denatured for 10min at 408C, 438C,
468C, 498C, 528C and 558C. Dimers and monomers were electrophoresed in a 1% native agarose gel and probed with an HIV-1 riboprobe. The
temperature at which the RNA dimers fully dissociate into monomers is marked with an arrow.
952 Nucleic Acids Research, 2009, Vol. 37,No. 3usage bias in HIV-1 replication that has not yet been
explored. HIV-1, like all retroviruses, packages two
copies of its RNA genome covalently linked near the 50
end. The tertiary structure of HIV-1’s dimeric RNA
genome is essential for viral cDNA synthesis, the transla-
tion of viral proteins and the assembly and maturation of
viral particles (53). These multifaceted roles require that
the RNA genome can interact with itself as well as viral
NL4255a A
B
time time
C NL h*p2-NC53 WT
cDNA
Unextended
primer
Figure 6. Partial codon modiﬁcation of the HIV-1 genome results in viral particles with decreased reverse transcription activity. (A) The location and
orientation of HIV-1 speciﬁc primers used to amplify viral DNA in real-time PCR is depicted. The primer pair AA55/M667 was used to amplify the
minus-strand ssDNA. The primer pair M661/M667 was used to amplify complete HIV-1 cDNA (cDNA). (B) Freshly isolated PBMCs were
stimulated with PHA for three days prior to infection with the WT (NL4.3) and mutant virions. Samples were lysed 24h post-infection for analysis
of reverse transcription products by real-time PCR. Results are shown as copies of viral DNA per million cells. (C) In vitro extension of DNA
primers on codon-modiﬁed and WT RNA templates with primer NL4255a. Ten nanomolars of primer/template were extended with 10nM of HIV-1
RT
E478Q for 0s, 30s, 1min, 5min, 15min, 30min and 60min. Reaction products were analyzed on denaturing 8% polyacrylamide-urea gels and
quantiﬁed with a Bioimager. These ﬁgures are representative of three distinct experiments.
Cell only
NL4.3
NL h*CA173-NC53/PR17-23
NL h*CA173-NC53/PR17-RT483
NL h*PR23-RT483
Figure 7. Partial codon modiﬁcation of the HIV-1 genome does not impact upon viral entry. A mock infected cell only control was used to record
the background levels of blue cells. Percentage of blue cells indicates the relative amounts of WT and codon-modiﬁed HIV-1 to enter MT2 cells. No
detectable diﬀerence was observed between WT and codon-modiﬁed HIV-1 to enter T-lymphocytes. This ﬁgure is representative of three distinct
experiments.
Nucleic AcidsResearch, 2009, Vol.37,No. 3 953and host cell proteins, making a dynamic and structurally
versatile genome critical for optimal viral function (53,54).
While many of the RNA structures that mediate these
interactions are known (41,53,55–57), the knowledge of
RNA elements existing across the full length of the
HIV-1 genome is still in its infancy. Despite this, current
data consistently point to important roles for RNA struc-
ture in viral function. For example, cis-acting instability
elements (INS) are selected regions of high AU content
and AUUUA motifs within the HIV-1 viral genome. INS
have a well documented role in RNA stability and the
nuclear retention of unspliced and singly spliced HIV-1
mRNAs (58,59), which ultimately inﬂuence the expression
of viral proteins. Similarly, our understanding of the role
of RNA structures in virus–host interactions is also rap-
idly expanding and it appears that both viruses and hosts
actively compete for the control of the miRNA pathways
to facilitate their own survival (60–63).
The structural genes encoding gag, pol and env contain
multiple INS that make the protein expression dependent
on the Rev- and CRM1-nuclear export pathways. The
removal of the INS by codon modiﬁcation allows access
to Rev- and CRM1-independent nuclear export pathways
that are not utilized by HIV-1 (50,58,64). The most likely
explanation for the unchanged viral protein expression
observed in our G-rich full length HIV-1 mutants is that
in the context of the full-length HIV-1 genome, depen-
dency on HIV-1’s standard nuclear export pathways is
maintained as the INS and RRE RNA elements have
not been altered in env. As viral protein expression is
not aﬀected by the inclusion of these G-rich gag or pol
sequences in the full-length genome, the observed suppres-
sion of viral infectivity in these mutants indicates that the
A-rich sequences found in the HIV-1 genome have a role
in viral replication that is independent of viral protein
production levels.
In this study, we observed a subtle change in the intra-
cellular protein proﬁle of NL h
 PR23-RT463 with the
appearance of an additional band at 90kDa. Alterations
to protein processing may be explained by changes in the
kinetics of protein folding, which results from the antici-
pated change to RNA folding. Alternatively, there is evi-
dence to suggest that RNA is important for protein
processing in HIV-1 as the presence of RNA is required
for proteolytic cleavage of HIV-1 NCp15 (65,66). As
genomic RNA and the viral protease may interact for eﬃ-
cient cleavage of viral proteins, changing the RNA codons
and consequently altering RNA folding may aﬀect the
proper RNA–viral protease interaction required for viral
protein processing. It is also conceivable that this 90kDa
protein is derived from alternated spliced RNA that is
the by-product of codon modiﬁcation and the refolding
of HIV RNA genomes. Further experimentations are
required to validate these hypotheses.
We observed a correlation between the extent of the
replication defect and the increase in RNA dimer stability.
The increase in the stability of the RNA dimers may be
due in part to increased hydrogen bonding strength
between monomer strands of the G-rich mutants within
the codon-modiﬁed RNA sequences. The increased dimer
stability may also reﬂect a modiﬁcation of RNA elements
in pol that are required for normal dimer formation. The
Dimerization Initiation Site (DIS) stem-loop (SL1) is the
primary site involved in RNA dimer formation, while
the DIS is indeed the nucleation point for genomic
RNA dimerization, additional RNA sequences along the
genome participate in RNA dimer formation (53). The
involvement of additional sequences has been suggested
by the ﬁnding that partial or complete deletion of the
DIS stem loop does not abolish the formation of dimeric
RNA (30). Moreover, evidence from avian retroviruses
(67,68) has suggested that retroviral RNA interacts at
multiple sites along the genome. The HIV-1 vector
system used by Sakuragi et al. (69) provided some of the
ﬁrst evidence that RNA elements within pol may in fact
negatively regulate the stability of RNA dimers (69).
Consistent with the observation by Sakuragi et al. (69),
the introduction of the codon-modiﬁed sequences may
have obstructed the ‘RNA elements’ in pol required for
normal RNA dimer formation, generating more stable
dimers akin to those identiﬁed (69) when the pol region
was deleted.
All three codon-modiﬁed constructs displayed greatly
impaired reverse transcription (Figure 6B). Altering the
codon bias of HIV-1 genomic RNA may impair viral
infectivity by altering the conformation of the genomic
RNA incorporated into the virion, so that the reverse
transcription complex is rendered non-functional due to
impaired interactions between the viral RNA and NC and
other factors such as RNA helicase (70). Alternatively, the
negative eﬀects on reverse transcription may be due to
changes in RNA structure that hinder the polymerases
path, this notion is supported by in vitro reverse transcrip-
tion assay where codon-modiﬁed RNA templates are less
eﬃcient to support the synthesis of viral cDNA than
native HIV-1 RNA genome (Figure 6C). Unsuitable sec-
ondary structures introduced by codon modiﬁcation may
cause abortive reverse transcription, and this interpreta-
tion is consistent with previous reports showing RNA con-
formation is an important determinant for the synthesis of
viral cDNA (71).
In this study, we have shown that A-rich structurally
poor RNA sequences in HIV-1 genomes are not merely
‘records’ of hypermutations during viral evolution. These
elements inﬂuence RNA dimer stability and are important
for viral cDNA synthesis. Further investigations are
needed to reveal the precise mechanistic contribution to
HIV-1 biology and/or the regulation of RNA networks
within the infected host cells.
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